Oct 23, 2015

Bioingenium initiates a patentability study to protect the developments made in ComplexInc Project

ComplexINC partner Bioingenium, a biotech company based in Barcelona, has announced the initiation of a patentability study that will be used to select and protect the intellectual property of the new developments carried out by the company during the ComplexINC project. The different innovations performed by Bioingenium are focused in the engineering of yeasts cells for expression of therapeutic...
Oct 21, 2015

Maren Bleckmann, HZI PhD student, awarded with an ACTIP Fellowship 2015/2016

The HZI PhD student Maren Bleckmann was recognized with the ACTIP (Animal Cell Technology Industrial Platform) Fellowship 2015/16 for her work to optimize protein expression in insect cells. Her application was deemed “very good” by the ACTIP evaluators, and scored particularly high for its impact on animal cell practices. She is invited to present her work at the ACTIP meeting at the 3-4...
Oct 20, 2015

ComplexINC Presents at Frontiers of Membrane Protein Biology Meeting in Oxford, UK

The exploits and project results of the ComplexINC consortium were presented at the Frontiers of Integral Membrane Protein Structural Biology (FIMPSB) meeting at Oxford University, organized by Prof Liz Carpenter and the Structural Genomics Consortium (SGC). Imre Berger, ComplexINC coordinator and invited speaker at the meeting, gave a lecture providing insights into the technological advances...
Oct 19, 2015

Helmholtz Centre for Infection Research invited to present at 12th PEACe Conference in San Diego

Joop van den Heuvel of Helmholtz Centre for Infection Research (HZI), partner in the ComplexINC project funded by the EC, was invited to present the innovative work on stable cell line engineering at the 12th Protein Expression in Animal Cells (PEACe) conference held in San Diego, California from 20 to 24 of September. The presentation “Generation of stable CHO multi RMCE expression cell lines”...
Oct 12, 2015

Exclusive Option on Intellectual Property Granted to Geneva Biotech

The University of Geneva has granted Geneva Biotech an exclusive option on intellectual property arising from a research collaboration to discover small molecule type 2 diabetes therapeutics using ComplexINC-developed platform technologies, and University of Geneva-owned diabetes preclinical models.
Displaying results 6 to 10 out of 46